LC–MS strategies for advanced modalities: ADC, AOC, multidomain and RNA therapeutics

Wednesday 08 April 2026

16:00 [CEST] 10:00 [EDT] 07:00 [PDT]

Alternative time zones 

Learn practical approaches for measuring all components of your molecule from scientific experts at BioAgilytix in this live 45-minute webinar and Q&A.

Liquid chromatography–mass spectrometry (LC–MS) is a powerful platform for pharmacokinetic (PK) assessment across diverse therapeutic modalities, offering high specificity through detection of signature protein sequences and reduced susceptibility to matrix interference. For complex modalities—including antibody–drug conjugates (ADCs), antibody–oligonucleotide conjugates (AOCs), multimeric proteins and RNA therapeutics—LC–MS enables simultaneous measurement of multiple drug species, reduced reliance on critical reagents, and robust, regulatory-compliant analyses. This webinar will highlight LC–MS-based strategies for the detection of novel drug modalities to support accurate, reliable and fit-for-purpose PK analysis.

 

REGISTER NOWWhat will you learn?Who may this interest?Speakers


What you will learn?

  • The advantages of LC–MS platforms for PK assessment for complex modalities like ADCs, RNA therapeutics and multimeric proteins.
  • Best practices and recommendations for method development and validation of these complex molecules via LC–MS.
  • How to overcome common challenges of LC–MS method development.

Who may this interest?

  • Translational biologists
  • Clinical pharmacologists
  • Clinical operations
  • Bioanalytical scientists
  • LC–MS analytical chemists

Lynn Kamen
Scientific Officer, Executive Director
BioAgilytix

Lynn Kamen is a Scientific Officer, Executive Director at BioAgilytix. She received her PhD in Immunology at the University of Michigan (MI, USA) and completed a postdoctoral fellowship in Immunology at the University of California San Francisco (CA, USA). Lynn is an accomplished scientific leader with over 15 years of experience in drug development, with deep technical expertise across large molecules, small molecules and advanced therapy medicinal products (ATMPs). Her experience spans multiple therapeutic areas, including oncology, cancer immunotherapy, immunology, ophthalmology and neurology.

Dave Beyerlein 
Global LC–MS Lead, Vice President and General Manager
BioAgilytix

Dave Beyerlein is the Vice President and General Manager of the BioAgilytix San Diego, California lab and LC–MS Global Lead. With over 30 years of LC–MS experience, he is a Co-founder of MicroConstants in San Diego, acquired by BioAgilytix in 2021. After joining the BioAgilytix team, Dave has expanded LC–MS services globally to Durham, North Carolina and Hamburg, Germany. Dave also assists with method development and the ongoing LC–MS expansion at 360biolabs, a BioAgilytix company, in Australia.

Shashank Gorityala 
Associate Director
BioAgilytix

Shashank Gorityala, PhD, is an Associate Director and heads the LC–MS services at BioAgilytix’s North Carolina headquarters, where he leads large-molecule LC–MS bioanalysis across regulated and exploratory programs. He brings more than 10 years of experience working with complex modalities, including biologics, ADCs, oligonucleotides and novel biomarkers. Shashank has co-authored industry-collaborative thought leadership articles within the bioanalytical community and has delivered invited talks through webinars, workshops and podcasts. His work emphasizes the practical implementation of LC–MS in regulated bioanalysis, advancement of large-molecule workflows, and alignment of science, data quality and decision-making.

Ben Nie
Manager II
BioAgilytix

Ben Nie, PhD, is a Manager and Principal Investigator at BioAgiltyix, specializing in LC–MS method development for large molecules and biologics. With over 10 years of experience, he focuses on advancing analytical strategies for monoclonal antibodies (mAbs), ADCs, protein biomarkers and oligonucleotides, supporting PK/TK and biomarker assay development. He has authored more than 20 peer-reviewed publications and is recognized for expertise in applying LC–MS technologies to complex biotherapeutic analyses.

In association with: